Inovio Pharmaceuticals, Inc.
corporate_fare Company Profile
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for INO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for INO spans 10-Q, 8-K, 424B5, FWP.
Recent high-impact activity:
- Inovio Posts $49.2M Q3 Loss as First Commercial Launch of VOCERYQ Takes Shape
- Inovio Q3: $49.2M Loss, $48.4M Cash, Going Concern Pushed to Late Q4 2027
- Inovio Finalizes $80.5M Net Raise as Underwriters Take Full Option
- Inovio Prices $75M Offering at $1.05, a 28% Discount to Last Sale, Days After First FDA Approval
- Inovio Prices $75M Offering at $1.05, a 15% Discount to Thursday's Close
Financial Snapshot
Short Interest & Short Volume
1.82 days to coverFINRA reported short interest of 22,100,943 shares in INO as of the October 30, 2026 settlement, a 3.7% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 38.0% of INO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for INO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.
Offering Priced at $1.05 Per Share · Net Proceeds of About $70M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →